Display options
Cite
Najafian N, Weber AT, Zuckerman JE, et al. AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia. Dig Dis Sci. 2021;67(1):67-70doi: 10.1007/s10620-021-07253-2.
Najafian, N., Weber, A. T., Zuckerman, J. E., Zhang, S., Saab, S., & Choi, G. (2022). AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia. Digestive diseases and sciences, 67(1), 67-70. https://doi.org/10.1007/s10620-021-07253-2
Najafian, Nilofar, et al. "AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia." Digestive diseases and sciences vol. 67,1 (2022): 67-70. doi: https://doi.org/10.1007/s10620-021-07253-2
Najafian N, Weber AT, Zuckerman JE, Zhang S, Saab S, Choi G. AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia. Dig Dis Sci. 2022 Jan;67(1):67-70. doi: 10.1007/s10620-021-07253-2. Epub 2021 Oct 15. PMID: 34655012.
Copy Download .nbib Format: NLM
Share it on

Dig Dis Sci. 2022 Jan;67(1):67-70. doi: 10.1007/s10620-021-07253-2. Epub 2021 Oct 15.

AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia.

Digestive diseases and sciences

Nilofar Najafian, Andrew T Weber, Jonathan E Zuckerman, Sarah Zhang, Sammy Saab, Gina Choi

Affiliations

  1. Departments of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
  2. Departments of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
  3. Departments of Medicine, University of California at Los Angeles, Los Angeles, CA, USA. [email protected].
  4. Departments of Surgery, University of California at Los Angeles, Los Angeles, CA, USA. [email protected].
  5. Departments of Nursing, University of California at Los Angeles, Los Angeles, CA, USA. [email protected].
  6. Pfleger Liver Institute, UCLA Medical Center, 200 Medical Plaza, Suite 214, Los Angeles, CA, 90095, USA. [email protected].
  7. Departments of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.

PMID: 34655012 DOI: 10.1007/s10620-021-07253-2

Abstract

A patient with systemic amyloidosis developed portal hypertension, acute liver failure and multiorgan dysfunction. Extensive testing was unrevealing for paraproteinemia, plasma cell dyscrasia, infectious, or inflammatory conditions. He was transferred to our institution for orthotopic liver transplant evaluation but was ultimately declined given clinical instability and dysautonomia. Post-mortem evaluation revealed extensive amyloid deposition in multiple organs determined to be AL-lambda amyloidosis.

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Keywords: Acute liver failure; Amyloid; Portal hypertension

References

  1. Voulgarelis M, Mitroulis I, Tzioufas AG. Amyloidosis. In: Efthimiou P, ed. Springer: Cham; 2019; 297–311. - PubMed
  2. Staron A, Kataria Y, Murray DL, Sloan JM, Sanchorawala V. Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes. Am J Hematol. 2020;95:E45–E48. https://doi.org/10.1002/ajh.25685 . - PubMed
  3. Benson MD, Liepnieks JJ, Kluve-Beckerman B. Hereditary systemic immunoglobulin light-chain amyloidosis. Blood. 2015;125:3281–3286. https://doi.org/10.1182/blood-2014-12-618108 . - PubMed
  4. Levine RA. Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients. Am J Med. 1962;33:349–357. doi: https://doi.org/10.1016/0002-9343(62)90231-0 - PubMed
  5. Norero B, Perez-Ayuso RM, Duarte I, Ramirez P, Soza A, Arrese M et al. Portal hypertension and acute liver failure as uncommon manifestations of primary amyloidosis. Ann Hepatol. 2013;13:142–149. - PubMed
  6. Real de Asua D, Costa R, Galvan JM, Filigheddu MT, Trujillo D, Cadinanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014;6:369–377. doi: https://doi.org/10.2147/CLEP.S39981 . - PubMed
  7. Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289:268–292. https://doi.org/10.1111/joim.13169 . - PubMed
  8. Li G, Han D, Wei S, Wang H, Chen L. Multiorgan involvement by amyloid light chain amyloidosis. J Int Med Res. 2019;47:1778–1786. https://doi.org/10.1177/0300060518814337 . - PubMed
  9. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82:291–298. https://doi.org/10.1097/01.md.0000091183.93122.c7 . - PubMed
  10. Vaxman I, Gertz M. When to suspect a diagnosis of amyloidosis. Acta Haematol. 2020;143:304–311. https://doi.org/10.1159/000506617 . - PubMed
  11. Wang YD, Zhao CY, Yin HZ. Primary hepatic amyloidosis: a mini literature review and five cases report. Ann Hepatol. 2012;11:721–727. - PubMed

Publication Types